Ein Multigen-Assay zur Vorhersage des Rückfalls bei Tamoxifen-behandeltem, lymphknotennegativem Brustkrebs

Paik et al. (Fri,) untersuchten diese Fragestellung.

www.synapsesocial.com/papers/69dbd2bff7e0c66ced83666d — DOI: https://doi.org/10.1056/nejmoa041588

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring· 1999 · 11,608 citations
2. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16.· 1990 · 295 citations
3. Breast cancer estrogen and progesterone receptor values: their distribution, degree of concordance, and relation to number of positive axillary nodes.· 1983 · 40 citations
4. Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer Prognosis· 1992 · 487 citations
5. 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*· 2001 · 885 citations